This preprint is under consideration at Journal of Ophthalmic Inflammation and Infection. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Original research
Douglas Kenneth Sigford
Tel-Aviv University
Corresponding Author
ORCiD: https://orcid.org/0000-0001-7152-0773
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Purpose
To investigate the contralateral effect of extended release steroid implants on cystoid macular edema (CME).
Methods
Retrospective study of patients with bilateral CME receiving intravitreal injections of long-acting intravitreal corticosteroid implants. Changes in CME and central subfield thickness (CST) in the contralateral eye on optical coherence tomography (OCT) were compared to an untreated control group.
Results
Thirteen study patients and 14 controls were included in the study. In the treatment group CST remained stable in all of the patients. Of the controls, CST worsened in 21.4% and remained stable in 78.6%. The mean CST (6.3 ± 30.3 vs. 27.5 ± 66.1 µm, p = 0.2) and the mean macular volume (0.08 ± 0.34 vs. -0.05 ± 0.21 mm3, P = 0.8) were not statistically different between the treatment group and control group.
Conclusion
In this study there was no statistically significant effect on CME of contralateral intravitreal corticosteroid implants.
Keywords
CST – Central Subfield Thickness, Macular Volume, Intravitreal extended release steroid injection, Contralateral eye, Dexamethasone intravitreal implant (Ozurdex), Fluocinolone acetonide intravitreal implant (ILUVIEN®)
Figure 1
Figure 2
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 19 Mar, 2021
No community comments so far
Editor assigned
On 14 Mar, 2021
Submission checks complete
On 14 Mar, 2021
Editor invited
On 14 Mar, 2021
First submitted
On 13 Mar, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Ophthalmology
Learn more about our company.
This preprint is under consideration at Journal of Ophthalmic Inflammation and Infection. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Original research
Douglas Kenneth Sigford
Tel-Aviv University
Corresponding Author
ORCiD: https://orcid.org/0000-0001-7152-0773
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 19 Mar, 2021
No community comments so far
Editor assigned
On 14 Mar, 2021
Submission checks complete
On 14 Mar, 2021
Editor invited
On 14 Mar, 2021
First submitted
On 13 Mar, 2021
Subject Areas
Ophthalmology
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Purpose
To investigate the contralateral effect of extended release steroid implants on cystoid macular edema (CME).
Methods
Retrospective study of patients with bilateral CME receiving intravitreal injections of long-acting intravitreal corticosteroid implants. Changes in CME and central subfield thickness (CST) in the contralateral eye on optical coherence tomography (OCT) were compared to an untreated control group.
Results
Thirteen study patients and 14 controls were included in the study. In the treatment group CST remained stable in all of the patients. Of the controls, CST worsened in 21.4% and remained stable in 78.6%. The mean CST (6.3 ± 30.3 vs. 27.5 ± 66.1 µm, p = 0.2) and the mean macular volume (0.08 ± 0.34 vs. -0.05 ± 0.21 mm3, P = 0.8) were not statistically different between the treatment group and control group.
Conclusion
In this study there was no statistically significant effect on CME of contralateral intravitreal corticosteroid implants.
Figure 1
Figure 2
Loading...